Europe beats US to approve Moderna’s combo flu-COVID shot

The European Commission has officially authorized Moderna’s mRNA-based combination vaccine targeting both influenza and COVID-19, marking a significant milestone in global immunization. Known as mRNA-1083 or mCOMBRIAX, this is the world’s first authorized shot that protects against both respiratory viruses in a single dose. The approval follows a positive review in February from a key European Medicines Agency committee, which cleared the regulatory path.

Notably, the vaccine was developed in the United States, yet it remains shelved there. Europe’s decision this week gives Moderna a crucial early foothold in the market, even as U. S. regulators continue to hold back.

Moderna CEO Stéphane Bancel welcomed the news, emphasizing the vaccine’s potential to streamline adult immunization. “By combining protection against two significant respiratory viruses in a single dose, our vaccine aims to simplify immunization for adults, particularly those at high risk,” Bancel said in a press release. “mCOMBRIAX offers an important new option for Europeans, while also aiming to strengthen the resilience of healthcare systems across Europe.”

The authorization underscores Europe’s willingness to embrace innovative vaccine technologies, even as the U. S. moves more cautiously. For Moderna, the approval provides a strategic advantage in the competitive respiratory vaccine market.